About O₂nix Bio
O₂nix Bio is an oncology therapeutics company developing pro-oxidant medicines designed to exploit oxidative stress vulnerabilities in metastatic cancer. Founded in 2025 and based in Boston, the company is building on more than a decade of foundational research in metastasis biology and RNA modifications, with peer-reviewed work published in Nature (2015) and Nature Cancer (2024).
Our Mission
To transform metastatic cancer from a terminal diagnosis into a manageable chronic disease by selectively targeting the stress-adaptation pathways metastatic tumors depend on for survival.
Our Approach
Metastasis kills most cancer patients, yet there are no FDA-approved therapies that specifically target metastatic spread. Standard of care is palliation.
We develop first-in-class small-molecule therapies that disable the redox-buffering machinery metastatic cells require to colonize distant organs and resist standard-of-care treatment. By layering our therapies onto established oncology regimens, we aim to deepen and prolong response, delay resistance, and extend patient survival.
Our lead program targets FTSJ1, an RNA-modifying enzyme central to the oxidative stress survival of metastatic tumors — a first-in-class druggable target. We are advancing this program in collaboration with Synfini Inc., an AI-driven drug discovery platform.
Why Now
Three converging shifts make this the moment to build a metastasis-targeted company:
RNA biology has matured into a drug discovery field. Storm Therapeutics, Tevard Biosciences, and Alltrna have attracted significant institutional capital, validating RNA modifications as a therapeutic axis.
AI-driven medicinal chemistry compresses cost and timeline. Through our Synfini partnership, industry-grade chemistry is accessible at the earliest stage — hit scaffolds in months, not years.
Metastasis is emerging as a distinct therapeutic category. A new generation of metastasis-focused biotechs has been funded over the past five years. O₂nix Bio is the only company at the intersection of redox biology, RNA epigenetics, and metastasis.